tuberculosis) strains that fulfil the definition of MDR/RR-TB and which are also resistant to any fluoroquinolone and at least one additional Group A drug* XDR-TB : TB caused by Mycobacterium tuberculosis(M. Pre-XDR-TB : TB caused by Mycobacterium tuberculosis(M.tuberculosis) strains that fulfil the definition of MDR/RR-TB and which are also resistant to any fluoroquinolone* The definition of MDR-TB will remain the same. Future-proof (i.e., that could be used for a certain period of time despite foreseen changes in practice).īearing these principles in mind, and cognizant of the current strategic and operational issues as described by meeting participants, the WHO proposes a definition of pre-XDR-TB as well as a revised definition of XDR-TB.Relevant to national TB programmes, including surveillance and clinical management, and.Meeting participants discussed recent developments in the areas of TB diagnosis, treatment and programming, potential future developments in these areas based on the research pipelines and suggested some overarching principles that should guide the development of a revised definition of XDR-TB, including that it should be:

Discuss a proposal for a new definition of XDR-TB that has global application and which can be used for clinical, surveillance and programmatic purposes.Discuss overarching principles that need to be borne in mind when thinking about a new definition of XDR-TB and.Discuss options for changing the definition of XDR-TB, including the pros and cons of these options with various perspectives and stakeholders in mind (including clinical, programmatic and surveillance perspectives).Discuss recent changes in treatment regimens and diagnostics for drug-resistant TB and to determine how these impact on the definition of XDR-TB.The pre-existing definition of XDR-TB was formulated in 2006 at a meeting of the Global Taskforce on XDR-TB, convened by WHO, and has been in use for clinical and surveillance purposes, since this time. The overall goal of the meeting was to discuss recent changes in treatment regimens and diagnostics for drug-resistant TB and to determine how these impact on the definition of XDR-TB, with a view to revising this definition.

Over 70 participants attended the meeting, representing countries, bilateral and multilateral agencies, international organizations, nongovernmental organizations, civil society and academia. The World Health Organization (WHO) consultation meeting on the definition of extensively drug resistant (XDR) tuberculosis (TB) was held on 27, 28 and 29 October 2020 as an online meeting, organized by the Global TB Programme, WHO, Geneva, Switzerland.

Session meaning